PE20200937A1 - Compuestos macrociclicos para tratar enfermedades - Google Patents
Compuestos macrociclicos para tratar enfermedadesInfo
- Publication number
- PE20200937A1 PE20200937A1 PE2020000787A PE2020000787A PE20200937A1 PE 20200937 A1 PE20200937 A1 PE 20200937A1 PE 2020000787 A PE2020000787 A PE 2020000787A PE 2020000787 A PE2020000787 A PE 2020000787A PE 20200937 A1 PE20200937 A1 PE 20200937A1
- Authority
- PE
- Peru
- Prior art keywords
- independently
- deuterium
- halogen
- alkyl
- macrocyclic compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Referido a compuestos macrociclicos de formula I, en donde cada L es independientemente -C(R1)(R2)- o X; X es O, S, S(O) o S(O)2; cada R1 y R2 es independientemente H, deuterio, halogeno, C1-C6 alquilo, entre otros; M es CR3 o N; M1 es CR4; cada R3, R4, y R5 es independientemente hidrogeno, deuterio, halogeno, entre otros; R6 es H, deuterio, C1-C6 alquilo, C2-C6 alquenilo, entre otros; R7 y R8 se combinan para formar un C3-C7 cicloalquilo, un heterocicloalquilo de 5 a 8 miembros, C6-C10 arilo, o heteroarilo de 5 a 7 miembros, entre otros; Y es O, S, NR9, o CR9R10; R9 y R10 son cada uno independientemente H, deuterio, halogeno, C1-C6 alquilo, C2-C6 alquenilo, entre otros; cada uno de Z1, Z2, Z3, Z4, Z5, y Z6 es independientemente N, NH, C o CH; p es 1, 2, 3, o 4; y t es 1, 2, 3, 4, o 5; o una sal farmaceuticamente aceptable del mismo. Tambien se refiere a composiciones farmaceuticas, metodos de preparacion de dichos compuestos, y metodo para inhibir receptor tirosina quinasa (RET) o SRC; siendo util en el tratamiento de enfermedades como el cancer.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607528P | 2017-12-19 | 2017-12-19 | |
| US201862727124P | 2018-09-05 | 2018-09-05 | |
| US201862779283P | 2018-12-13 | 2018-12-13 | |
| PCT/US2018/066158 WO2019126121A1 (en) | 2017-12-19 | 2018-12-18 | Macrocyclic compounds for treating disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20200937A1 true PE20200937A1 (es) | 2020-09-17 |
Family
ID=66992951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000787A PE20200937A1 (es) | 2017-12-19 | 2018-12-18 | Compuestos macrociclicos para tratar enfermedades |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10745416B2 (es) |
| EP (2) | EP3728271B1 (es) |
| JP (2) | JP7194188B2 (es) |
| KR (1) | KR102814342B1 (es) |
| CN (1) | CN111511746B (es) |
| AU (1) | AU2018392332B2 (es) |
| BR (1) | BR112020012319A2 (es) |
| CA (1) | CA3083674A1 (es) |
| CL (1) | CL2020001632A1 (es) |
| DK (1) | DK3728271T3 (es) |
| EC (1) | ECSP20033467A (es) |
| ES (1) | ES2929467T3 (es) |
| HR (1) | HRP20221502T1 (es) |
| HU (1) | HUE060711T2 (es) |
| IL (1) | IL275265B2 (es) |
| JO (1) | JOP20200152A1 (es) |
| LT (1) | LT3728271T (es) |
| MX (1) | MX2020006490A (es) |
| PE (1) | PE20200937A1 (es) |
| PH (1) | PH12020550901A1 (es) |
| PL (1) | PL3728271T3 (es) |
| PT (1) | PT3728271T (es) |
| RS (1) | RS63787B1 (es) |
| SG (1) | SG11202005590PA (es) |
| SI (1) | SI3728271T1 (es) |
| SM (1) | SMT202200443T1 (es) |
| TW (1) | TW201930312A (es) |
| WO (1) | WO2019126121A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| BR112020007593A2 (pt) | 2017-10-18 | 2020-09-24 | Incyte Corporation | derivados de imidazol condensados substituídos por grupos hidróxi terciários como inibidores de pi3k-gama |
| PL3728271T3 (pl) * | 2017-12-19 | 2023-01-23 | Turning Point Therapeutics, Inc. | Związki makrocykliczne do leczenia chorób |
| ES2898364T3 (es) | 2017-12-19 | 2022-03-07 | Bristol Myers Squibb Co | Acidos carbamoilciclohexílicos ligados a N triazol como antagonistas de LPA |
| ES2970041T3 (es) | 2018-04-03 | 2024-05-24 | Blueprint Medicines Corp | Inhibidor de RET para su uso en el tratamiento del cáncer que tiene una alteración de RET |
| WO2020033838A2 (en) | 2018-08-10 | 2020-02-13 | Blueprint Medicines Corporation | Treatment of egfr-mutant cancer |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| CN113490664B (zh) | 2018-10-22 | 2025-05-16 | 阿鲁米斯公司 | Tyk2抑制剂和其用途 |
| WO2020257189A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles for treating disease |
| JP2022537385A (ja) * | 2019-06-19 | 2022-08-25 | ターニング・ポイント・セラピューティクス・インコーポレイテッド | 大環状キナーゼ阻害剤の多形 |
| WO2020257165A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles for use in treating disease |
| WO2021027503A1 (zh) * | 2019-08-12 | 2021-02-18 | 罗欣药业(上海)有限公司 | 三环类化合物、其制备方法、中间体及应用 |
| CA3163735A1 (en) * | 2019-12-03 | 2021-06-10 | Turning Point Therapeutics, Inc. | Macrocycles for use in treating disease |
| BR112022024382A2 (pt) | 2020-05-29 | 2023-05-02 | Blueprint Medicines Corp | Formas sólidas de pralsetinibe |
| WO2021244609A1 (zh) | 2020-06-04 | 2021-12-09 | 成都倍特药业股份有限公司 | 具有大环结构的化合物及其用途 |
| WO2022032026A1 (en) | 2020-08-05 | 2022-02-10 | C4 Therapeutics, Inc. | Compounds for targeted degradation of ret |
| CN116635076A (zh) * | 2020-12-17 | 2023-08-22 | 荣山医药股份有限公司 | 大环化合物及其用途 |
| WO2023060022A1 (en) * | 2021-10-05 | 2023-04-13 | Turning Point Therapeutics, Inc. | Synthesis of macrocyclic compounds |
| JP2025524018A (ja) * | 2022-07-22 | 2025-07-25 | メッドシャイン ディスカバリー インコーポレイテッド | 三環式環含有大環状化合物及びその使用 |
| EP4573095A1 (en) * | 2022-08-17 | 2025-06-25 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| JP7571173B2 (ja) | 2023-02-24 | 2024-10-22 | キヤノン株式会社 | 撮像装置、撮像装置の制御方法、及びプログラム |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU679053B2 (en) * | 1993-03-25 | 1997-06-19 | Pharmacia & Upjohn Company | Indoletetralins having dopaminergic activity |
| TW425397B (en) | 1993-12-07 | 2001-03-11 | Lilly Co Eli | Novel bis-indolemaleimide macrocycle derivatives their preparation process, intermediates for their preparation and their use as Protein Kinase C inhibitors |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| JP2004526676A (ja) | 2000-12-08 | 2004-09-02 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | キナーゼ阻害剤として有用な大員複素環式化合物 |
| US8815872B2 (en) | 2008-09-08 | 2014-08-26 | Merck Patent Gmbh | Macrocyclics pyrimidines as aurora kinase inhibitors |
| SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
| ES2900243T3 (es) | 2008-10-22 | 2022-03-16 | Array Biopharma Inc | Compuestos de pirazolo[1,5-a]pirimidina sustituidos como inhibidores de trk quinasa |
| EP2962566A1 (en) | 2008-10-31 | 2016-01-06 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| MX2012004426A (es) | 2009-10-13 | 2012-07-30 | Elanco Animal Health Ireland | Inhibidores macrociclicos de integrasa. |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| MX2012013467A (es) | 2010-05-20 | 2013-04-29 | Array Biopharma Inc | Compuestos macrociclicos como inhibidores de trk cinasa. |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| CA2817785A1 (en) * | 2010-11-19 | 2012-05-24 | Toby Blench | Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| US9238604B2 (en) | 2011-08-19 | 2016-01-19 | Merck Sharp & Dohme Corp. | Process and intermediates for preparing macrolactams |
| HUE027318T2 (en) | 2011-09-30 | 2016-10-28 | Oncodesign Sa | Macrocyclic FLT3 kinase inhibitors |
| BR112014022106B1 (pt) | 2012-03-06 | 2022-08-02 | Pfizer Inc | Derivados macrocíclicos, combinação, composição e usos na fabricação de um medicamento para o tratamento de doenças |
| US8946415B2 (en) | 2012-03-09 | 2015-02-03 | Lexicon Pharmaceuticals, Inc. | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use |
| US8969565B2 (en) | 2012-03-09 | 2015-03-03 | Lexicon Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| US9714258B2 (en) * | 2014-01-24 | 2017-07-25 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| EP3172213B1 (en) * | 2014-07-21 | 2021-09-22 | Dana-Farber Cancer Institute, Inc. | Macrocyclic kinase inhibitors and uses thereof |
| JP6871903B2 (ja) | 2015-07-02 | 2021-05-19 | ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子 |
| WO2017007759A1 (en) | 2015-07-06 | 2017-01-12 | Tp Therapeutics, Inc. | Diaryl macrocycle polymorph |
| PT3733187T (pt) | 2015-07-21 | 2024-11-08 | Turning Point Therapeutics Inc | Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro |
| JP6802850B2 (ja) * | 2016-03-03 | 2020-12-23 | 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． | 大環状化合物および該化合物を含む組成物 |
| CN106008531B (zh) * | 2016-05-30 | 2019-01-11 | 上海交通大学 | 多环稠合大环内酰胺类化合物的抗胰腺癌用途 |
| JP2019527230A (ja) | 2016-07-28 | 2019-09-26 | ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 大環状キナーゼ阻害剤 |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| HRP20241197T1 (hr) | 2017-07-28 | 2024-11-22 | Turning Point Therapeutics, Inc. | Makrociklični spojevi i primjene istih |
| BR112020007593A2 (pt) | 2017-10-18 | 2020-09-24 | Incyte Corporation | derivados de imidazol condensados substituídos por grupos hidróxi terciários como inibidores de pi3k-gama |
| EP3728270A4 (en) * | 2017-12-19 | 2021-06-23 | Turning Point Therapeutics, Inc. | MACROCYCLIC KINASE INHIBITORS AND THEIR USES |
| ES2898364T3 (es) | 2017-12-19 | 2022-03-07 | Bristol Myers Squibb Co | Acidos carbamoilciclohexílicos ligados a N triazol como antagonistas de LPA |
| PL3728271T3 (pl) | 2017-12-19 | 2023-01-23 | Turning Point Therapeutics, Inc. | Związki makrocykliczne do leczenia chorób |
| GB201721235D0 (en) | 2017-12-19 | 2018-01-31 | Syngenta Participations Ag | Polymorphs |
| WO2019120267A1 (zh) | 2017-12-22 | 2019-06-27 | 成都先导药物开发股份有限公司 | 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂 |
| AU2019254979B2 (en) | 2018-04-18 | 2021-08-12 | Hitgen Inc. | Macrocyclic kinase inhibitor |
-
2018
- 2018-12-18 PL PL18893293.3T patent/PL3728271T3/pl unknown
- 2018-12-18 JP JP2020533594A patent/JP7194188B2/ja active Active
- 2018-12-18 KR KR1020207017739A patent/KR102814342B1/ko active Active
- 2018-12-18 SM SM20220443T patent/SMT202200443T1/it unknown
- 2018-12-18 WO PCT/US2018/066158 patent/WO2019126121A1/en not_active Ceased
- 2018-12-18 CN CN201880082563.6A patent/CN111511746B/zh active Active
- 2018-12-18 RS RS20221099A patent/RS63787B1/sr unknown
- 2018-12-18 HR HRP20221502TT patent/HRP20221502T1/hr unknown
- 2018-12-18 CA CA3083674A patent/CA3083674A1/en active Pending
- 2018-12-18 AU AU2018392332A patent/AU2018392332B2/en not_active Ceased
- 2018-12-18 JO JOP/2020/0152A patent/JOP20200152A1/ar unknown
- 2018-12-18 PE PE2020000787A patent/PE20200937A1/es unknown
- 2018-12-18 PT PT188932933T patent/PT3728271T/pt unknown
- 2018-12-18 SG SG11202005590PA patent/SG11202005590PA/en unknown
- 2018-12-18 LT LTEPPCT/US2018/066158T patent/LT3728271T/lt unknown
- 2018-12-18 EP EP18893293.3A patent/EP3728271B1/en active Active
- 2018-12-18 HU HUE18893293A patent/HUE060711T2/hu unknown
- 2018-12-18 SI SI201830779T patent/SI3728271T1/sl unknown
- 2018-12-18 EP EP22191652.1A patent/EP4151641A1/en active Pending
- 2018-12-18 BR BR112020012319-6A patent/BR112020012319A2/pt unknown
- 2018-12-18 ES ES18893293T patent/ES2929467T3/es active Active
- 2018-12-18 DK DK18893293.3T patent/DK3728271T3/da active
- 2018-12-18 MX MX2020006490A patent/MX2020006490A/es unknown
- 2018-12-19 TW TW107145927A patent/TW201930312A/zh unknown
-
2020
- 2020-01-30 US US16/777,717 patent/US10745416B2/en active Active
- 2020-05-05 US US16/866,983 patent/US11286265B2/en active Active
- 2020-06-10 IL IL275265A patent/IL275265B2/en unknown
- 2020-06-15 PH PH12020550901A patent/PH12020550901A1/en unknown
- 2020-06-17 CL CL2020001632A patent/CL2020001632A1/es unknown
- 2020-06-19 EC ECSENADI202033467A patent/ECSP20033467A/es unknown
-
2022
- 2022-02-14 US US17/670,665 patent/US20220306652A1/en not_active Abandoned
- 2022-12-09 JP JP2022197141A patent/JP2023027237A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200937A1 (es) | Compuestos macrociclicos para tratar enfermedades | |
| PE20200700A1 (es) | Compuestos macrociclicos y usos de los mismos | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| CY1124239T1 (el) | Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου | |
| MX2019004113A (es) | Compuestos farmaceuticos. | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| PE20180742A1 (es) | Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| PE20231380A1 (es) | Macrociclicos que contienen una anillo de 1,3,4-oxadiazol para su uso como moduladores del regulador de la conductancia transmembrana de la fibrosis quistica | |
| AR059905A1 (es) | Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto | |
| PE20240687A1 (es) | Compuestos de indazol como inhibidores de cinasas | |
| PE20201165A1 (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| MX2022006475A (es) | Compuestos triciclicos sustituidos. | |
| UY28578A1 (es) | Derivados de amida | |
| PE20181851A1 (es) | Moduladores alostericos de receptores de acetilcolina nicotinicos | |
| PE20191260A1 (es) | Compuestos inhibidores del vih | |
| PE20231190A1 (es) | Degradadores de moleculas pequenas de piperidinilo de helios y procedimientos de uso | |
| PE20161372A1 (es) | Inhibidores de dihidropirrolopiridina de ror-gamma | |
| PE20180949A1 (es) | Nuevos derivados hidroxiacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR061015A1 (es) | Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto | |
| MX2019006296A (es) | Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas. | |
| PE20181491A1 (es) | Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| PE20161251A1 (es) | Compuestos heteroarilo o arilo biciclicos fusionados y su uso como inhibidores de irak4 | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
| UY29316A1 (es) | Miméticos de glucocorticoides, métodos para prepararlos, composiciones farmacéuticas, y usos de los mismos. |